{
  "id": 18099103,
  "title": "How I'd Invest $10,000 Right Now",
  "url": "https://urgent.news/2026/11/04/how-id-invest-10-000-right-now",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-04T09:00:02.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/11/04/how-i-d-invest-usd10-000-right-now/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Investing $10,000 wisely in today's stock market can be a challenge due to rising interest rates, high valuations, and political uncertainty affecting stocks. While the S&P 500 has traditionally been a solid move for long-term investors, it now has significant exposure to overvalued tech stocks, which may not suit risk-averse investors. To achieve a better balance of risk and reward, I would consider investing in three types of assets: the Schwab U.S. Dividend Equity ETF (SCHD -0.97%), Verizon Communications (VZ +0.42%), and Viking Therapeutics (VKTX -2.76%).\n\nFirst, I would allocate $5,000 to the Schwab U.S. Dividend ETF, which offers diversification and substantial dividend income. The ETF's yield of 3.2% is much higher than the S&P 500's average yield of 1.1%. It holds about 100 quality stocks, ensuring safe dividend payments and minimizing risk exposure. Over the past year, the ETF has gained 30%, proving its value amid market uncertainty. By investing $5,000 in this ETF, half of the portfolio is secured with a well-diversified fund.\n\nNext, I would invest $3,000 in Verizon Communications, a stock that has been undervalued due to speculation about its future in the mobile carrier market. With a price-to-earnings ratio of 11 and a yield of 6.3%, Verizon offers an attractive combination of affordability and income. Its payout ratio of 72% indicates a safe dividend payout. Allocating $3,000 to this stock would lock up $8,000 of the portfolio into income-generating assets.\n\nFinally, I would direct the remaining $2,000 to Viking Therapeutics, a small healthcare company with a promising GLP-1 treatment called VK2735. If approved, this treatment could significantly boost Viking's stock value. Although the company has faced mixed reactions in the market, I believe its promising clinical trial results and potential acquisition by a larger healthcare firm make it a worthwhile investment. However, due to the higher risk associated with this investment, allocating only $2,000 to Viking Therapeutics is a more appropriate strategy.\n\nBy balancing these three investments, I believe this portfolio offers a good mix of stability, dividends, and growth potential, making it a suitable choice for the current market conditions.",
  "summary": "Tracking the S&P 500 may not be optimal anymore, and there can be better ways for investors to gain a mix of dividends, stability, and growth.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}